Promising combo for prostate cancer falls short: trial ends early

NCT ID NCT04179864

Terminated Disease control Sponsor: Epizyme, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth better than standard treatment alone. The trial was terminated early, meaning it did not meet its goals or faced challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Academisch Ziekenhuis Groeninge Campus Kennedylaan

Kortrijk, West Vlaanderen, Belgium
Associated Medical Professionals of NY, PLLC - Urology

Syracuse, New York, 13210, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Clinica Universidad de Navarra

Pamplona, Spain
Comprehensive Cancer Centers of Nevada - Central Valley

Las Vegas, Nevada, 89169, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Genesis Healthcare Partners

San Diego, California, 92123, United States
Hematology Oncology Associates of the Treasure Coast

Port Saint Lucie, Florida, 34952, United States
Hospital Clinico San Carlos

Madrid, Spain
Hospital Universitario 12 de Octubre

Madrid, Spain
Hospital Universitario La Paz

Madrid, Spain
Hospital Universitario de Jerez de la Frontera

Jerez de la Frontera, Cadiz, Spain
Hospital de la Santa Creu i. Sant Pau

Barcelona, Spain
Hospital del Mar Parc de Salut Mar

Barcelona, Spain
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Montefiore Einstein Center for Cancer Care

The Bronx, New York, 10461, United States
SCRI - Tennessee Oncology Chattanooga

Chattanooga, Tennessee, 37404, United States
SCRI - Tennessee Oncology Nashville

Nashville, Tennessee, 37203, United States
The Urology Center Of Colorado

Denver, Colorado, 80211, United States
University of Pittsburgh Medical Center - Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Urology Associates P.C.

Hendersonville, Tennessee, 37075, United States
Urology San Antonio

San Antonio, Texas, 78229, United States
XCancer - Northwest Oncology and Hematology

Rolling Meadows, Illinois, 60008, United States
XCancer - Tennesee Cancer Specialists

Knoxville, Tennessee, 37909, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.